高级检索
当前位置: 首页 > 详情页

Citrus fruit intake and lung cancer risk: A meta-analysis of observational studies

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Shanghai Jiao Tong Univ, Shanghai Tongren Hosp, Hongqiao Int Inst Med, Sch Publ Hlth,Sch Med, 277 South Chongqing Rd, Shanghai 200025, Peoples R China [2]Shanghai Jiao Tong Univ, Shanghai Tongren Hosp, Hongqiao Int Inst Med, Sch Med,Clin Res Inst, 277 South Chongqing Rd, Shanghai 200025, Peoples R China [3]Univ Hawaii, Canc Epidemiol Program, Ctr Canc, 701 Ilalo St, Honolulu, HI 96813 USA [4]Shanghai Shenkang Hosp, Dev Ctr, Shanghai Clin Res Promot & Dev Ctr, 2 Kangding Rd, Shanghai 200041, Peoples R China
出处:
ISSN:

关键词: Citrus fruit Lung cancer Meta-analysis Dose-response meta-analysis

摘要:
Objective: To explore the hypothesis that Citrus intake may reduce the risk of lung cancer. Design: Meta-analyses of Dichotomy and dose-response relationship. Data sources: We searched online literature databases including PubMed, Embase, and Cochrane Library to screen relevant articles available up to 27 July 2020. Search terms included (i) Citrus, Fruit, Diet, Dietary; (ii) cancer, neoplasm, tumor (iii)lung; (iv)case-control, cohort, prospective. Study selection: The selection of studies and the meta-analysis were carried out by following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The following inclusion criteria were chosen: (i) epidemiological studies with case-control or cohort design; (ii) human participants; (iii) studies investigated the relationship between Citrus fruit intake and lung cancer risk; (iv) if data were duplicated in more than two studies, we brought the most recent or all-sided study into this analysis. We collected all full-text articles that met the inclusion criteria. We applied the following exclusion criteria to the full-text articles, including possible articles listed by manual search: (i) there was no represented odds ratio (OR) or relative risk (RR) estimate and its corresponding 95 % confidence interval (95 % CI) (or data to calculate them) for the highest versus lowest levels of Citrus fruit consumption (ii) reviews, systematic reviews and meta-analyses; (iii) there was no data of Citrus fruit intake at the individual level. Data extraction: Two reviewers independently performed the extraction of data from eligible studies. Statistical methods: Adjusted odds ratios (ORs) and 95 % CIs were combined and weighted by the method of "Dersimonian and Laird" to produce pooled ORs using a random-effects model. Moreover, we utilized the method reported by "Longnecker and Greenland" to evaluate linear trends and 95 % CIs by the ORs' natural logs and corresponding CIs from categories of Citrus intake. Finally, we evaluated the risk of publication bias and selection bias by inspecting for asymmetry in the pre-specified funnel plots of the study OR against the standard error of the OR's logarithm and by "Egger's test". Results: We included twenty-one studies in the final review. Pooled analyses suggested that those with the highest Citrus fruit intake compared to the lowest intake had a 9% reduction in lung cancer risk [OR 0.91 (95 % CI 0.84-0.98)]. We found a nonlinear association between Citrus intake and lung cancer risk in the dose-response analysis (p = 0.0054) and that the risk reached the minimum (OR = 0.91) around 60 g/d. However, no obvious dose-response association was observed with intakes above 80 g/d. Conclusion: We found that Citrus fruit intake was negatively associated with the risk of lung cancer. Besides, there was a nonlinear dose-response relationship between Citrus intake and lung cancer risk within a certain range.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版
大类 | 2 区 医学
小类 | 2 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 1 区 药学
JCR分区:
出版当年[2019]版:
Q1 PHARMACOLOGY & PHARMACY
最新[2024]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2024版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Shanghai Jiao Tong Univ, Shanghai Tongren Hosp, Hongqiao Int Inst Med, Sch Publ Hlth,Sch Med, 277 South Chongqing Rd, Shanghai 200025, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [2]Shanghai Jiao Tong Univ, Shanghai Tongren Hosp, Hongqiao Int Inst Med, Sch Med,Clin Res Inst, 277 South Chongqing Rd, Shanghai 200025, Peoples R China [4]Shanghai Shenkang Hosp, Dev Ctr, Shanghai Clin Res Promot & Dev Ctr, 2 Kangding Rd, Shanghai 200041, Peoples R China [*1]Shanghai Clinical Research Promotion and Development Center, Shanghai Shenkang Hospital Development Center, No. 2 Kangding Road, Shanghai 200041, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:29032 今日访问量:0 总访问量:1619 更新日期:2025-10-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)